In a strategic move to reduce reliance on foreign tech giants, Japan launches a national AI initiative, combining SoftBank's leadership with substantial government backing to develop a domestic foundational model.
As copper prices surge over 40% since August, driven by supply constraints and green energy demand, investors are eyeing major producers BHP, Freeport-McMoRan, and Southern Copper, each offering a distinct path to exposure in the red-hot market.
Finnish technology leader Valmet introduces a new line of bio-based press roll covers, backed by specific lifecycle assessment data, to help paper manufacturers reduce fossil resource dependence and track emissions.
Shares of Corcept Therapeutics plunged 16% after a corrected FDA letter disclosed the agency had repeatedly cautioned the company against filing its application for a Cushing's syndrome drug, which was later rejected over efficacy and safety concerns.
The United States and Guatemala have formally signed a reciprocal trade agreement designed to dismantle barriers for American exporters and deepen economic integration in the region, officials announced Friday.
CareDx CEO John Hanna sold over 19,000 shares under a pre-arranged trading plan, a move that comes as the transplant diagnostics firm posts strong revenue growth but continues to navigate a challenging stock market environment.
The automotive safety giant posted historic sales and cash flow in 2025, powered by explosive growth with Chinese automakers and in India. While navigating a softer production forecast and tariff headwinds, management projects margin expansion for 2026.
With the specter of U.S. military action looming, Iran is engaging in a frantic diplomatic push with regional powers like Turkey, while global capitals scramble to prevent a full-scale war. Despite the outreach, analysts warn the window for de-escalation is narrowing.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
The Eurozone economy expanded by 1.5% in 2025, outpacing forecasts despite ongoing trade tensions with the US, as a recovery in Germany and robust growth in Spain helped offset a slowdown in France.
Maersk Air Cargo is ending its trans-Pacific Boeing 767 operations and partnership with Amerijet International, opting for larger Boeing 777 freighters. The move will result in pilot furloughs at Amerijet and signals a strategic pivot towards more efficient long-haul air cargo networks.
Electro Optic Systems (EOS), the Australian firm behind a landmark high-energy laser contract, is planning a strategic move of its headquarters and listing to Europe within the year, its CEO reveals, aiming to embed itself at the heart of the continent's urgent defence modernisation drive.
We put the AI chatbot to the test, asking if a savvy $1,000 investment in 2015 could have grown to $1 million by 2025. The answer reveals the extreme rarity of such returns in mainstream markets and highlights the stark difference between hindsight and feasible strategy.
While major indices tread water ahead of key earnings, a segment of the market continues to buzz with activity. We examine three micro-cap companies—Hongli Group, Royalty Management, and CreateAI—whose financial profiles and strategic moves are capturing attention from investors willing to navigate the high-risk, high-reward penny stock arena.
Mizuho Securities raised its rating on Applied Materials (AMAT) to Outperform, with a $370 price target, forecasting accelerated growth in global wafer fab equipment spending driven by major chipmakers' capital expenditure plans.
